206 related articles for article (PubMed ID: 10730687)
1. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction.
Swan SK; Hursting MJ
Pharmacotherapy; 2000 Mar; 20(3):318-29. PubMed ID: 10730687
[TBL] [Abstract][Full Text] [Related]
2. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects.
Swan SK; St Peter JV; Lambrecht LJ; Hursting MJ
Pharmacotherapy; 2000 Jul; 20(7):756-70. PubMed ID: 10907966
[TBL] [Abstract][Full Text] [Related]
3. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
Guzzi LM; McCollum DA; Hursting MJ
J Thromb Thrombolysis; 2006 Dec; 22(3):169-76. PubMed ID: 17103051
[TBL] [Abstract][Full Text] [Related]
4. Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia.
Keyl C; Zimmer E; Bek MJ; Wiessner M; Trenk D
Thromb Haemost; 2016 Jun; 115(6):1081-9. PubMed ID: 26792118
[TBL] [Abstract][Full Text] [Related]
5. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
Stangier J; Stähle H; Rathgen K; Fuhr R
Clin Pharmacokinet; 2008; 47(1):47-59. PubMed ID: 18076218
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
Beiderlinden M; Werner P; Bahlmann A; Kemper J; Brezina T; Schäfer M; Görlinger K; Seidel H; Kienbaum P; Treschan TA
BMC Anesthesiol; 2018 Feb; 18(1):18. PubMed ID: 29426286
[TBL] [Abstract][Full Text] [Related]
8. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease.
Murray PT; Reddy BV; Grossman EJ; Hammes MS; Trevino S; Ferrell J; Tang I; Hursting MJ; Shamp TR; Swan SK
Kidney Int; 2004 Dec; 66(6):2446-53. PubMed ID: 15569338
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban.
Tran JQ; Di Cicco RA; Sheth SB; Tucci M; Peng L; Jorkasky DK; Hursting MJ; Benincosa LJ
J Clin Pharmacol; 1999 May; 39(5):513-9. PubMed ID: 10234600
[TBL] [Abstract][Full Text] [Related]
10. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
[TBL] [Abstract][Full Text] [Related]
11. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Stangier J; Rathgen K; Stähle H; Mazur D
Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
[TBL] [Abstract][Full Text] [Related]
12. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.
Levine RL; Hursting MJ; McCollum D
Chest; 2006 May; 129(5):1167-75. PubMed ID: 16685006
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters.
Akimoto K; Klinkhardt U; Zeiher A; Niethammer M; Harder S
J Clin Pharmacol; 2011 Jun; 51(6):805-18. PubMed ID: 20663996
[TBL] [Abstract][Full Text] [Related]
14. Extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer.
Kubiak DW; Szumita PM; Fanikos JR
Ann Pharmacother; 2005 Jun; 39(6):1119-23. PubMed ID: 15886289
[TBL] [Abstract][Full Text] [Related]
15. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulant activity and pharmacokinetic properties of a sub-cutaneously administered mixed micellar formulation of argatroban in experimental animals.
Berry CN; Lunven C; Lecoffre C; Lainée P; O'Connor SE; André F; Roger B; Garrigou-Gadenne D; Rouchouse A; Roome NO; Vivan N
Thromb Haemost; 2000 Aug; 84(2):278-85. PubMed ID: 10959701
[TBL] [Abstract][Full Text] [Related]
17. Effect of renal function on the pharmacodynamics of argatroban.
Arpino PA; Hallisey RK
Ann Pharmacother; 2004 Jan; 38(1):25-9. PubMed ID: 14742788
[TBL] [Abstract][Full Text] [Related]
18. Lack of pharmacokinetic interactions between argatroban and warfarin.
Brown PM; Hursting MJ
Am J Health Syst Pharm; 2002 Nov; 59(21):2078-83. PubMed ID: 12434720
[TBL] [Abstract][Full Text] [Related]
19. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.
Bartholomew JR; Pietrangeli CE; Hursting MJ
Drugs Aging; 2007; 24(6):489-99. PubMed ID: 17571914
[TBL] [Abstract][Full Text] [Related]
20. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
Eriksson UG; Johansson S; Attman PO; Mulec H; Frison L; Fager G; Samuelsson O
Clin Pharmacokinet; 2003; 42(8):743-53. PubMed ID: 12846595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
